menu
    • menu
    [{"orgOrder":0,"company":"Nuravax","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"AV-1959R","moa":"||Amyloid-beta\/Tau","graph1":"Neurology","graph2":"Phase I","graph3":"Nuravax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuravax \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Nuravax \/ National Institutes of Health"},{"orgOrder":0,"company":"Nuravax","sponsor":"Arvax","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"AV-1959R","moa":"Amyloid-beta\/Tau","graph1":"Neurology","graph2":"Phase I","graph3":"Nuravax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuravax \/ Arvax","highestDevelopmentStatusID":"6","companyTruncated":"Nuravax \/ Arvax"},{"orgOrder":0,"company":"Nuravax","sponsor":"National Institute on Aging | Institute for Molecular Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"DUVAX","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"Phase I","graph3":"Nuravax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuravax \/ National Institute on Aging | Institute for Molecular Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Nuravax \/ National Institute on Aging | Institute for Molecular Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals by Nuravax

    Menu

    Nuravax

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nuravax

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Nuravax

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DUVAX

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : National Institute on Aging | Institute for Molecular Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

                            Details : DUVAX is a Vaccine drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 26, 2025

                            Lead Product(s) : DUVAX

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : National Institute on Aging | Institute for Molecular Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nuravax

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Nuravax

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV-1959R,AV-1980R

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Duvax Alzheimer's Vaccine Wins $3M NIH Grant for U.S. Clinical Trials

                            Details : The funding aims to advance the clinical development of Duvax, the first dual-target. It is being evaluated for the treatment of Alzheimer Disease.

                            Product Name : Duvax

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 05, 2025

                            Lead Product(s) : AV-1959R,AV-1980R

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nuravax

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Nuravax

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV-1959R

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Arvax

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine

                            Details : Abeta (AV-1959R) is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Abeta

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 18, 2025

                            Lead Product(s) : AV-1959R

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Arvax

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth